Novo Nordisk sues over Sanofi's Solostar

Forbes reports "Sanofi-Aventis said it will 'vigorously' defend its rights to ensure the availability of its products after Danish drug company Novo Nordisk said it is suing the French pharmaceutical group over patent infrigement relating to Solostar, its insulin-delivery pen."

In the federal court system, service of a complaint can occur well after the filing of the complaint. Forbes noted: "Sanofi-Aventis has not yet been served with a complaint by Novo and our understanding of Novo's allegation is very preliminary,' a spokesman for Sanofi-Aventis told Thomson Financial."

The case was apparently filed in the Trenton vicinage of DNJ.